L E Abrey

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Treatment for primary CNS lymphoma: the next step
    L E Abrey
    Departments of Neurology and Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 18:3144-50. 2000
  2. ncbi A phase II trial of temozolomide for patients with recurrent or progressive brain metastases
    L E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Neurooncol 53:259-65. 2001
  3. pmc Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report
    S A Grimm
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 71:1355-60. 2008
  4. ncbi Temozolomide for treating brain metastases
    L E Abrey
    Department of Neurology at Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 28:34-42. 2001
  5. ncbi Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines
    D D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 18:1145-51. 2007
  6. ncbi Combination immunochemotherapy followed by reduced dose (rd) whole brain radiation therapy (WBRT) in an expanded cohort of patients with newly diagnosed primary central nervous system lymphoma (PCNSL)
    L E Abrey
    Memorial Sloan Kettering Cancer Center, New York, NY Northwestern University, Chicago, IL Columbia University, New York, NY University of Virginia, Charlottesville, VA University of Vermont, Burlington, VT
    J Clin Oncol 27:2072. 2009
  7. ncbi Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM)
    A M P Omuro
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:2028. 2011
  8. ncbi Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report
    S A Grimm
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 18:1851-5. 2007
  9. ncbi Cognitive functions in survivors of primary central nervous system lymphoma
    D D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Neurology 62:548-55. 2004
  10. pmc Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
    F M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Neurology 73:1200-6. 2009

Collaborators

Detail Information

Publications20

  1. ncbi Treatment for primary CNS lymphoma: the next step
    L E Abrey
    Departments of Neurology and Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 18:3144-50. 2000
    ..The reported protocol was designed to optimize and enhance the chemotherapeutic component of treatment...
  2. ncbi A phase II trial of temozolomide for patients with recurrent or progressive brain metastases
    L E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Neurooncol 53:259-65. 2001
    ..Treatment options for patients with recurrent brain metastases are extremely limited. This study was designed to determine the safety and efficacy of temozolomide in the treatment of recurrent or progressive brain metastases...
  3. pmc Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report
    S A Grimm
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 71:1355-60. 2008
    ..To describe the demographics, diagnostic details, therapeutic management, and outcome in patients with primary CNS lymphoma (PCNSL) with ocular involvement...
  4. ncbi Temozolomide for treating brain metastases
    L E Abrey
    Department of Neurology at Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 28:34-42. 2001
    ..017), primarily in patients with newly diagnosed brain and lung metastases...
  5. ncbi Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines
    D D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 18:1145-51. 2007
    ..There is, however, a paucity of research on cognitive functions in this population...
  6. ncbi Combination immunochemotherapy followed by reduced dose (rd) whole brain radiation therapy (WBRT) in an expanded cohort of patients with newly diagnosed primary central nervous system lymphoma (PCNSL)
    L E Abrey
    Memorial Sloan Kettering Cancer Center, New York, NY Northwestern University, Chicago, IL Columbia University, New York, NY University of Virginia, Charlottesville, VA University of Vermont, Burlington, VT
    J Clin Oncol 27:2072. 2009
    ..We conducted a prospective trial incorporating rituximab (R) and rdWBRT and previously demonstrated this was feasible. This study was extended to assess the long-term outcome of this approach in an expanded cohort...
  7. ncbi Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM)
    A M P Omuro
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:2028. 2011
    ..Due to radioprotective effects, BEV also allows for more aggressive RT schedules such as HFSRT. We initiated a phase II trial in newly diagnosed GBM utilizing HFSRT, BEV and TMZ...
  8. ncbi Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report
    S A Grimm
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 18:1851-5. 2007
    ..Primary intraocular lymphoma (PIOL) is an uncommon subset of primary central nervous system lymphoma. Because it is rare and difficult to diagnose, the natural history and optimal management are unknown...
  9. ncbi Cognitive functions in survivors of primary central nervous system lymphoma
    D D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Neurology 62:548-55. 2004
    ..This combined regimen prolongs patient survival, but also carries a substantial risk for delayed neurotoxicity particularly in the elderly. However, cognitive outcome evaluations have not been included in most clinical trials...
  10. pmc Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
    F M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Neurology 73:1200-6. 2009
    ..However, patterns of relapse, prognosis, and outcome of further therapy after bevacizumab failure have not been studied systematically...
  11. ncbi Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM)
    A B Lassman
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:2028. 2008
    ..However, the patterns of relapse and prognosis of patients (pts) with GBM following BEV have not been studied systematically. This may have important implications for efficacy analysis of post-BEV therapies...
  12. ncbi FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET following hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV), and temozolomide (TMZ) for glioblastoma (GBM)
    C Grommes
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:2048. 2011
    ..We sought to evaluate the relationships between different imaging modalities and anti-tumor activity in a prospective phase II trial of BEV, TMZ and HFSRT in GBM...
  13. ncbi Pseudoprogression (PsPr) after concurrent radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM)
    J L Clarke
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:2025. 2008
    ..However, there is growing evidence that radiographic and even clinical worsening may result from effects of therapy, i.e. PsPr, rather than from true PD...
  14. ncbi Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01
    L Nayak
    Memorial Sloan Kettering Cancer Center, New York, NY Dana Farber Cancer Institute, Boston, MA M D Anderson Cancer Center, Houston, TX Duke University Medical Center, Durham, NC University of California, San Francisco, San Francisco, CA
    J Clin Oncol 29:2039. 2011
    ..To confirm these results, a multicenter phase II trial was initiated through the former NABTC, now Adult Brain Tumor Consortium...
  15. ncbi Maintenance rituximab for CNS lymphoma
    D E Ney
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 26:2087. 2008
    ..The use of maintenance therapy in this patient population has not been rigorously studied...
  16. ncbi Phase II trial of temozolomide (TMZ) followed by myeloablative chemotherapy with autologous peripheral blood progenitor cell rescue (APBPCR) for newly diagnosed anaplastic oligodendroglioma: An Oligodendroglioma Study Group trial
    T J Kaley
    Memorial Sloan Kettering Cancer Center, New York, NY Northwestern Memorial Hospital, Chicago, IL Evanston Hospital, Evanston, IL Lahey Clinic Medical Center, Burlington, MA Massachusetts General Hospital, Boston, MA University of Calgary, Calgary, AB, Canada
    J Clin Oncol 27:2055. 2009
    ..We previously reported results using induction PCV chemotherapy; subsequently the induction regimen was changed to temozolomide (TMZ) which is reported here...
  17. ncbi Characteristics and outcomes of elderly patients with primary CNS lymphoma (PCNSL)
    D E Ney
    Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 27:2070. 2009
    ..The optimal treatment has yet to be determined. The aim of this study was to characterize older patients with PCNSL at our institution and identify outcomes related to treatment...
  18. doi Bacterial and fungal meningitis in patients with cancer
    J E Safdieh
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, USA
    Neurology 70:943-7. 2008
    ..To analyze cases of bacterial and fungal meningitis in patients with cancer...
  19. ncbi Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial
    A M Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, 10021, USA
    J Neurooncol 78:277-80. 2006
    ..Disease was stable in 6 of 18 patients and the median survival was 27 weeks. This regimen was well tolerated and a phase II trial using a dose of 30 mg/m2 of vinorelbine is warranted...
  20. ncbi Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma
    J J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Abbott Hall, Room 1123, 710 North Lake Shore Drive, Chicago, IL 60611, USA
    J Neurooncol 71:173-80. 2005
    ..Patients often have complete responses but relapses are common. We characterized the MR spectra of PCNSL patients, correlated MRSI with MRI and evaluated whether early recurrence could be detected by MRSI...